首页>投融资
PrognomiQ
D轮
PrognomIQ, a spin-out of Seer, is a healthcare company focused on the development and commercialization of multi-omics human tests for cancer and other diseases.In September 2020, Seer Inc announced that it has spun out and completed the initial financing of $55M for a newly formed healthcare company, PrognomIQ, Inc..In September 2021, Seer, Inc announced that it has spun out and completed the initial financing of $55M for PrognomIQ, Inc
基本信息
-
公司全称PrognomIQ Inc
-
类型早期疾病测试产品开发商
-
产业领域检测服务、器械/设备、试剂/耗材
-
公司人数15~50人
-
地址1900 Alameda de las Pulgas Suite 100 SAN MATEO CALIFORNIA 94403; US;
-
联系电话
-
邮箱info@prognomiq.com
-
成立时间2020-01-01
投融资
-
2024-11-05D轮3400万美元SeerCatalio Capital ManagementaMoonInvusBruker
-
2022-03-15未透露4600万美元Catalio Capital ManagementInvusMaverick CapitalaMoonEmerson CollectiveWing VenturesT. Rowe Price富达国际Bruker
-
2020-09-15未公开5500万美元aMoonWing VenturesEmerson CollectiveMaverick CapitalInvusT. Rowe Price富达国际
相关投融资企业
D轮
PrognomIQ, a spin-out of Seer, is a healthcare company focused on the development and commercialization of multi-omics human tests for cancer and other diseases.In September 2020, Seer Inc announced that it has spun out and completed the initial financing of $55M for a newly formed healthcare company, PrognomIQ, Inc..In September 2021, Seer, Inc announced that it has spun out and completed the initial financing of $55M for PrognomIQ, Inc
未透露
RareCyte Inc is a life science research and diagnostic development company focused on characterizing and isolating rare cells in the blood.In September 2021, RareCyte Inc completed a $24M financing
收并购
MDNA Life Sciences是线粒体DNA科学的先驱。 我们的使命是创建广泛的专有测试组合，从而显着改善诊断，治疗，预后和监测。 结束影响全世界患者的不必要的外科手术，疼痛和不确定性。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息